This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2007 Oct 20;25(30):4705-6.

doi: 10.1200/JCO.2007.13.1037.

Taming glioblastoma: targeting angiogenesis

Eric T Wong, Steven Brem

PMID: 17947716
DOI: 10.1200/JCO.2007.13.1037

Editorial

Taming glioblastoma: targeting angiogenesis

Eric T Wong et al. J Clin Oncol. 2007.

. 2007 Oct 20;25(30):4705-6.

doi: 10.1200/JCO.2007.13.1037.

Authors

Eric T Wong, Steven Brem

PMID: 17947716
DOI: 10.1200/JCO.2007.13.1037

No abstract available

PubMed Disclaimer

Comment on

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Vredenburgh JJ, et al. J Clin Oncol. 2007 Oct 20;25(30):4722-9. doi: 10.1200/JCO.2007.12.2440. J Clin Oncol. 2007. PMID: 17947719 Clinical Trial.

Similar articles

Bevacizumab plus irinotecan in recurrent glioblastoma.
Chamberlain MC. Chamberlain MC. J Clin Oncol. 2008 Feb 20;26(6):1012-3; author reply 1013. doi: 10.1200/JCO.2007.15.1605. J Clin Oncol. 2008. PMID: 18281677 No abstract available.
Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.
Fellah S, Girard N, Chinot O, Cozzone PJ, Callot V. Fellah S, et al. J Clin Oncol. 2011 Apr 10;29(11):e308-11. doi: 10.1200/JCO.2010.32.6082. Epub 2011 Jan 24. J Clin Oncol. 2011. PMID: 21263101 No abstract available.
Taming glioblastoma by targeting angiogenesis: 3 years later.
Wong ET, Brem S. Wong ET, et al. J Clin Oncol. 2011 Jan 10;29(2):124-6. doi: 10.1200/JCO.2010.32.5282. Epub 2010 Dec 6. J Clin Oncol. 2011. PMID: 21135277 No abstract available.
Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.
Nagaiah G, Almubarak M, Khan M, Altaha R. Nagaiah G, et al. Cancer Invest. 2010 Dec;28(10):1048-53. doi: 10.3109/07357907.2010.483499. Epub 2010 Sep 27. Cancer Invest. 2010. PMID: 20873990 Review.
Topoisomerase I inhibitors for the treatment of brain tumors.
Feun L, Savaraj N. Feun L, et al. Expert Rev Anticancer Ther. 2008 May;8(5):707-16. doi: 10.1586/14737140.8.5.707. Expert Rev Anticancer Ther. 2008. PMID: 18471044 Review.

See all similar articles

Cited by

Sevoflurane inhibits cell proliferation and migration of glioma by targeting the miR‑27b/VEGF axis.
Zhan X, Lei C, Yang L. Zhan X, et al. Mol Med Rep. 2021 Jun;23(6):408. doi: 10.3892/mmr.2021.12047. Epub 2021 Mar 31. Mol Med Rep. 2021. PMID: 33786635 Free PMC article.
Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model.
Jahnke K, Muldoon LL, Varallyay CG, Lewin SJ, Kraemer DF, Neuwelt EA. Jahnke K, et al. Neuro Oncol. 2009 Apr;11(2):142-50. doi: 10.1215/15228517-2008-077. Epub 2008 Sep 4. Neuro Oncol. 2009. PMID: 18772353 Free PMC article.
Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study.
Park KJ, Kano H, Iyer A, Liu X, Niranjan A, Flickinger JC, Lieberman FS, Lunsford LD, Kondziolka D. Park KJ, et al. J Neurooncol. 2012 Apr;107(2):323-33. doi: 10.1007/s11060-011-0744-9. Epub 2011 Nov 5. J Neurooncol. 2012. PMID: 22057917
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L, Mikkelsen T. Zuniga RM, et al. J Neurooncol. 2009 Feb;91(3):329-36. doi: 10.1007/s11060-008-9718-y. Epub 2008 Oct 25. J Neurooncol. 2009. PMID: 18953493 Clinical Trial.
Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma.
Funakoshi Y, Hata N, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Takigawa K, Mizoguchi M. Funakoshi Y, et al. Pharmaceuticals (Basel). 2020 Dec 16;13(12):470. doi: 10.3390/ph13120470. Pharmaceuticals (Basel). 2020. PMID: 33339404 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.